Design Therapeutics (DSGN) Revenue & Revenue Breakdown
Design Therapeutics Revenue Highlights
Design Therapeutics Revenue by Period
Design Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $226.00 | -72.90% |
| 2019-12-31 | $834.00 | - |
Design Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Design Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $838.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2020-09-30 | $20.00K | -35.48% |
| 2020-06-30 | $31.00K | -78.17% |
| 2020-03-31 | $142.00K | - |
Design Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Design Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IMCR | Immunocore | $249.43M | $75.40M |
| ADCT | ADC Therapeutics SA | $69.56M | $17.03M |
| AADI | Aadi Bioscience | $24.35M | $6.18M |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| MGTA | Dianthus Therapeutics | $314.00K | $72.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| ALVR | AlloVir | - | - |
| ALXO | ALX Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| GRPH | LENZ Therapeutics | - | - |
| ERAS | Erasca | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
DSGN Revenue FAQ
What is Design Therapeutics’s yearly revenue?
Design Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. DSGN's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is Design Therapeutics’s quarterly revenue?
Design Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). DSGN's quarterly revenue for Q4 2023 was $838K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Design Therapeutics’s revenue growth rate?
Design Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -100.00%.